Cork Cancer Research Centre, Mercy University Hospital and Leslie C. Quick Jnr. Laboratory, University College Cork, Ireland.
Cancer Lett. 2008 Apr 8;262(1):94-102. doi: 10.1016/j.canlet.2007.11.042. Epub 2008 Jan 7.
We investigated if the range of efficacy of a gene-based immunotherapy of solid tumours against systemic disease could be extended when used as a neoadjuvant to surgery. Hundred percent mice whose subcutaneous tumours were surgically removed 4 days post-electroporation with GM-CSF and B7-1 plasmid were systemically resistance to tumour rechallenge. In mice bearing both subcutaneous and hepatic tumours, neoadjuvant treatment of the primary tumour resulted in significant reduction in, or elimination of, hepatic tumour growth, with a significant increase in survival, indicating that control of the primary tumour by immunotherapy was not a prerequisite for containment of systemic disease.
我们研究了一种基于基因的免疫疗法对实体瘤的疗效范围，如果将其作为手术的辅助治疗是否可以扩大。在电穿孔 GM-CSF 和 B7-1 质粒 4 天后接受手术切除皮下肿瘤的小鼠中，100%对肿瘤再挑战具有全身耐药性。在患有皮下和肝肿瘤的小鼠中，对原发性肿瘤进行新辅助治疗可显著减少或消除肝肿瘤生长，并显著提高存活率，表明免疫疗法控制原发性肿瘤不是控制全身疾病的先决条件。
